Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Onconova Therapeutic (NQ: ONTX )

0.7200 -0.0200 (-2.70%)
Streaming Delayed Price Updated: 3:22 PM EDT, Oct 3, 2023 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Press Releases about Onconova Therapeutic

Onconova Therapeutics to Present a Late-Breaking Abstract on Rigosertib at the 2023 EADV Congress
From Onconova Therapeutics, Inc.
Via GlobeNewswire
Onconova Therapeutics to Participate at the H.C. Wainwright 25th Annual Global Investment Conference
From Onconova Therapeutics, Inc.
Via GlobeNewswire
Onconova Therapeutics Reports Corporate Update and Announces Second Quarter 2023 Financial Results
From Onconova Therapeutics, Inc.
Via GlobeNewswire
Onconova Therapeutics to Provide Corporate Update and Announce Second Quarter 2023 Financial Results on August 10, 2023
Company to host conference call and webcast at 4:30 p.m. ET on Thursday, August 10, 2023 
From Onconova Therapeutics, Inc.
Via GlobeNewswire
Onconova Therapeutics Presents Preclinical Data on Narazaciclib at the 17th International Conference on Malignant Lymphoma
Narazaciclib demonstrated significant synergistic anti-cancer activity in multiple in vivo models of mantle cell lymphoma (MCL) when combined with ibrutinib, the current standard-of-care 
From Onconova Therapeutics, Inc.
Via GlobeNewswire
Onconova Therapeutics Announces Poster Presentation at the American Society of Clinical Oncology Annual Meeting
Trial in Progress poster detailed design of Phase 2 program evaluating rigosertib monotherapy in advanced squamous cell carcinoma complicating recessive dystrophic epidermolysis bullosa 
From Onconova Therapeutics, Inc.
Via GlobeNewswire
Onconova Therapeutics Announces Dosing of First Participant in Investigator-Sponsored Phase 2 Trial of Rigosertib Plus Pembrolizumab in Metastatic Melanoma Patients Refractory to Immune Checkpoint Blockade
From Onconova Therapeutics, Inc.
Via GlobeNewswire
Onconova Therapeutics Reports First Quarter 2023 Financial Results and Provides Business Update
Conference call and live webcast at 4:30 p.m. ET today 
From Onconova Therapeutics, Inc.
Via GlobeNewswire
Onconova Therapeutics to Participate in Ladenburg Thalmann Virtual R&D Showcase on Narazaciclib in Endometrial Cancer
From Onconova Therapeutics, Inc.
Via GlobeNewswire
Onconova Therapeutics Doses First Patient in Phase 1/2a Trial of Narazaciclib Combined with Letrozole in Endometrial Cancer
From Onconova Therapeutics, Inc.
Via GlobeNewswire
Onconova Therapeutics to Present at the ISID International Epidermolysis Bullosa Symposium
From Onconova Therapeutics, Inc.
Via GlobeNewswire
Onconova Therapeutics to Provide Corporate Update and Announce First Quarter 2023 Financial Results on May 15, 2023
Company to host conference call and webcast at 4:30 p.m. ET on Monday, May 15, 2023 
From Onconova Therapeutics, Inc.
Via GlobeNewswire
Onconova Therapeutics Announces the Presentation of New Preclinical Data on Narazaciclib at the AACR Annual Meeting
Data further characterize narazaciclib’s mechanism of action and show its anti-cancer activity comparing favorably to that of FDA-approved CDK 4/6 inhibitors 
From Onconova Therapeutics, Inc.
Via GlobeNewswire
Onconova Therapeutics Announces the Unexpected Passing of Chief Medical Officer Dr. Mark Gelder
From Onconova Therapeutics, Inc.
Via GlobeNewswire
Onconova Therapeutics and Pangea Biomed Enter into Research Collaboration to Identify Biomarkers of Response to Rigosertib
From Onconova Therapeutics, Inc.
Via GlobeNewswire
Onconova Therapeutics Reports Full Year 2022 Financial Results and Provides Business Update
Conference call and live webcast at 4:30 p.m. ET today 
From Onconova Therapeutics, Inc.
Via GlobeNewswire
Onconova Therapeutics Announces Upcoming Poster Presentations at the AACR Annual Meeting
From Onconova Therapeutics, Inc.
Via GlobeNewswire
Onconova Therapeutics to Provide Corporate Update and Announce Fourth Quarter and Full Year 2022 Financial Results on March 16, 2023
Company to host conference call and webcast at 4:30 p.m. ET on Thursday, March 16, 2023 
From Onconova Therapeutics, Inc.
Via GlobeNewswire
Onconova Therapeutics Presents Preclinical Data Characterizing Rigosertib’s Mechanisms of Action at the AACR Targeting RAS Conference
From Onconova Therapeutics, Inc.
Via GlobeNewswire
Onconova Therapeutics Announces Additional Clinical Data Demonstrating Rigosertib’s Monotherapy Activity in RDEB-Associated Squamous Cell Carcinoma
From Onconova Therapeutics, Inc.
Via GlobeNewswire
Onconova Therapeutics to Present at the 2023 Guggenheim Oncology Conference
From Onconova Therapeutics, Inc.
Via GlobeNewswire
Onconova Therapeutics Announces Participation in the Channelchek Takeaway Series
From Onconova Therapeutics, Inc.
Via GlobeNewswire
Onconova Therapeutics Appoints Drs. Peter Atadja and Trafford Clarke to its Board of Directors
From Onconova Therapeutics, Inc.
Via GlobeNewswire
Onconova Therapeutics to Present at the Upcoming MedInvest Oncology Investor Conference
From Onconova Therapeutics, Inc.
Via GlobeNewswire
Onconova Therapeutics to Present at the Upcoming RHK Capital Disruptive Growth Conference
From Onconova Therapeutics, Inc.
Via GlobeNewswire
Onconova Therapeutics Announces Plans for a Phase 1/2a Trial of Narazaciclib Combined with Letrozole in Endometrial Cancer, Reports Third Quarter 2022 Financial Results, and Provides a Business Update
From Onconova Therapeutics, Inc.
Via GlobeNewswire
Onconova Therapeutics to Provide Corporate Update and Announce Third Quarter Financial Results on November 14, 2022
Company to host conference call and webcast at 4:30 p.m. Eastern Time on Monday, November 14, 2022 
From Onconova Therapeutics, Inc.
Via GlobeNewswire
Global Brain Tumor Diagnosis & Treatment Market Could Exceed $880 Million By 2027
Via FinancialNewsMedia
Why ‘Killer’ T Cells Could Boost COVID Immunity In Face Of New Variants
Via FinancialNewsMedia
Exposures COVID-19
Global Market For Sleep Aid Devices Could Reach $112.7 Billion By 2025
Via FinancialNewsMedia
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.